Form 4: PTC Therapeutics Executive VP Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Mark Elliott Boulding, Executive VP and CLO of PTC Therapeutics, sold shares of common stock to cover tax withholding obligations related to RSU vesting.
Summary
- Mark Elliott Boulding, an Executive VP and CLO at PTC Therapeutics, sold shares of common stock on February 19 and 20, 2025.
- The sales were executed to cover tax withholding obligations associated with the vesting of Restricted Stock Units (RSUs).
- On February 19, 2025, 1,333 shares were sold at a price of $50.096 per share.
- On February 20, 2025, 1,614 shares were sold at a price of $50.124 per share.
- Following these transactions, Boulding directly owns 103,901 shares of PTC Therapeutics common stock.
Sentiment
Score: 5
Explanation: The document is a routine disclosure of stock sales for tax purposes, indicating a neutral sentiment.
Industry Context
Sales of shares to cover tax obligations upon RSU vesting are a common practice among corporate executives.
Key Dates
| Date | Description |
|---|---|
| 02/15/2024 | Date of grant of 18,000 RSUs, of which 4,500 vested. |
| 02/15/2024 | Date of grant of 3,200 RSUs, of which 1,600 vested. |
| 02/19/2025 | Sale of 1,333 shares of common stock at $50.096. |
| 02/20/2025 | Sale of 1,614 shares of common stock at $50.124. |
| 02/21/2025 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.